REFERENCES
2. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219-34.
3. Parlani M, Jorgez C, Friedl P. Plasticity of cancer invasion and energy metabolism. Trends Cell Biol. 2023;33:388-402.
4. Ban XX, Wan H, Wan XX, et al. Copper metabolism and cuproptosis: molecular mechanisms and therapeutic perspectives in neurodegenerative diseases. Curr Med Sci. 2024;44:28-50.
5. Díez M, Cerdà FJ, Arroyo M, Balibrea JL. Use of the copper/zinc ratio in the diagnosis of lung cancer. Cancer. 1989;63:726-30.
6. Saleh SAK, Adly HM, Abdelkhaliq AA, Nassir AM. Serum levels of selenium, zinc, copper, manganese, and iron in prostate cancer patients. Curr Urol. 2020;14:44-9.
7. Adeoti ML, Oguntola AS, Akanni EO, Agodirin OS, Oyeyemi GM. Trace elements; copper, zinc and selenium, in breast cancer afflicted female patients in LAUTECH Osogbo, Nigeria. Indian J Cancer. 2015;52:106-9.
8. Xue Q, Kang R, Klionsky DJ, Tang D, Liu J, Chen X. Copper metabolism in cell death and autophagy. Autophagy. 2023;19:2175-95.
9. Tsang T, Posimo JM, Gudiel AA, Cicchini M, Feldser DM, Brady DC. Copper is an essential regulator of the autophagic kinases ULK1/2 to drive lung adenocarcinoma. Nat Cell Biol. 2020;22:412-24.
10. Brady DC, Crowe MS, Turski ML, et al. Copper is required for oncogenic BRAF signalling and tumorigenesis. Nature. 2014;509:492-6.
11. Guo J, Cheng J, Zheng N, et al. Copper promotes tumorigenesis by activating the PDK1-AKT oncogenic pathway in a copper transporter 1 dependent manner. Adv Sci. 2021;8:e2004303.
12. Parke A, Bhattacherjee P, Palmer RM, Lazarus NR. Characterization and quantification of copper sulfate-induced vascularization of the rabbit cornea. Am J Pathol. 1988;130:173-8.
13. Lopez J, Ramchandani D, Vahdat L. 12. Copper depletion as a therapeutic strategy in cancer. In: Essential metals in medicine: therapeutic use and toxicity of metal ions in the clinic. Berlin, Boston: De Gruyter, 2019; pp. 303-30.
14. Kuo MT, Huang YF, Chou CY, Chen HHW. Targeting the copper transport system to improve treatment efficacies of platinum-containing drugs in cancer chemotherapy. Pharmaceuticals. 2021;14:549.
15. Lukanović D, Herzog M, Kobal B, Černe K. The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancer. Biomed Pharmacother. 2020;129:110401.
16. Petruzzelli R, Polishchuk RS. Activity and trafficking of copper-transporting ATPases in tumor development and defense against platinum-based drugs. Cells. 2019;8:1080.
17. Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375:1254-61.
18. Zhang C, Huang T, Li L. Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives. J Hematol Oncol. 2024;17:68.
19. Gaetke LM, Chow CK. Copper toxicity, oxidative stress, and antioxidant nutrients. Toxicology. 2003;189:147-63.
20. Li Y, Ma J, Wang R, Luo Y, Zheng S, Wang X. Zinc transporter 1 functions in copper uptake and cuproptosis. Cell Metab. 2024;36:2118-29.e6.
21. Tang D, Chen X, Kroemer G. Cuproptosis: a copper-triggered modality of mitochondrial cell death. Cell Res. 2022;32:417-8.
22. Attar N, Campos OA, Vogelauer M, et al. The histone H3-H4 tetramer is a copper reductase enzyme. Science. 2020;369:59-64.
23. Grass G, Rensing C. CueO is a multi-copper oxidase that confers copper tolerance in Escherichia coli. Biochem Biophys Res Commun. 2001;286:902-8.
24. Kim JH, Matsubara T, Lee J, et al. Lysosomal SLC46A3 modulates hepatic cytosolic copper homeostasis. Nat Commun. 2021;12:290.
25. van den Berghe PV, Folmer DE, Malingré HE, et al. Human copper transporter 2 is localized in late endosomes and lysosomes and facilitates cellular copper uptake. Biochem J. 2007;407:49-59.
26. Qi Y, Yao Q, Li X, Li X, Zhang W, Qu P. Cuproptosis-related gene SLC31A1: prognosis values and potential biological functions in cancer. Sci Rep. 2023;13:17790.
27. Holzer AK, Manorek GH, Howell SB. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol. 2006;70:1390-4.
28. Song IS, Savaraj N, Siddik ZH, et al. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther. 2004;3:1543-9.
29. Lee YY, Choi CH, Do IG, et al. Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy. Gynecol Oncol. 2011;122:361-5.
30. Öhrvik H, Thiele DJ. The role of Ctr1 and Ctr2 in mammalian copper homeostasis and platinum-based chemotherapy. J Trace Elem Med Biol. 2015;31:178-82.
31. Yoshida H, Teramae M, Yamauchi M, et al. Association of copper transporter expression with platinum resistance in epithelial ovarian cancer. Anticancer Res. 2013;33:1409-14.
32. Furukawa T, Komatsu M, Ikeda R, Tsujikawa K, Akiyama S. Copper transport systems are involved in multidrug resistance and drug transport. Curr Med Chem. 2008;15:3268-78.
33. Sturtz LA, Diekert K, Jensen LT, Lill R, Culotta VC. A fraction of yeast Cu,Zn-superoxide dismutase and its metallochaperone, CCS, localize to the intermembrane space of mitochondria. A physiological role for SOD1 in guarding against mitochondrial oxidative damage. J Biol Chem. 2001;276:38084-9.
34. Wong PC, Waggoner D, Subramaniam JR, et al. Copper chaperone for superoxide dismutase is essential to activate mammalian Cu/Zn superoxide dismutase. Proc Natl Acad Sci U S A. 2000;97:2886-91.
35. Feng W, Ye F, Xue W, Zhou Z, Kang YJ. Copper regulation of hypoxia-inducible factor-1 activity. Mol Pharmacol. 2009;75:174-82.
36. Li Y, Liang R, Zhang X, et al. Copper chaperone for superoxide dismutase promotes breast cancer cell proliferation and migration via ROS-mediated MAPK/ERK signaling. Front Pharmacol. 2019;10:356.
37. Wang J, Luo C, Shan C, et al. Inhibition of human copper trafficking by a small molecule significantly attenuates cancer cell proliferation. Nat Chem. 2015;7:968-79.
38. Garza NM, Swaminathan AB, Maremanda KP, Zulkifli M, Gohil VM. Mitochondrial copper in human genetic disorders. Trends Endocrinol Metab. 2023;34:21-33.
39. Zhu SY, Zhou WQ, Niu YY, et al. COX17 restricts renal fibrosis development by maintaining mitochondrial copper homeostasis and restoring complex IV activity. Acta Pharmacol Sin. 2023;44:2091-102.
40. Huang D, Chen L, Ji Q, et al. Lead aggravates Alzheimer’s disease pathology via mitochondrial copper accumulation regulated by COX17. Redox Biol. 2024;69:102990.
41. Suzuki C, Daigo Y, Kikuchi T, Katagiri T, Nakamura Y. Identification of COX17 as a therapeutic target for non-small cell lung cancer. Cancer Res. 2003;63:7038-41.
42. Yang D, Xiao P, Qiu B, Yu HF, Teng CB. Copper chaperone antioxidant 1: multiple roles and a potential therapeutic target. J Mol Med. 2023;101:527-42.
43. Maghool S, Fontaine S, Roberts BR, Kwan AH, Maher MJ. Human glutaredoxin-1 can transfer copper to isolated metal binding domains of the P1B-type ATPase, ATP7B. Sci Rep. 2020;10:4157.
44. Mercer SW, La Fontaine S, Warr CG, Burke R. Reduced glutathione biosynthesis in Drosophila melanogaster causes neuronal defects linked to copper deficiency. J Neurochem. 2016;137:360-70.
45. Itoh S, Kim HW, Nakagawa O, et al. Novel role of antioxidant-1 (Atox1) as a copper-dependent transcription factor involved in cell proliferation. J Biol Chem. 2008;283:9157-67.
46. Dolgova NV, Nokhrin S, Yu CH, George GN, Dmitriev OY. Copper chaperone Atox1 interacts with the metal-binding domain of Wilson’s disease protein in cisplatin detoxification. Biochem J. 2013;454:147-56.
47. Palm-Espling ME, Andersson CD, Björn E, Linusson A, Wittung-Stafshede P. Determinants for simultaneous binding of copper and platinum to human chaperone Atox1: hitchhiking not hijacking. PLoS One. 2013;8:e70473.
48. Karginova O, Weekley CM, Raoul A, et al. Inhibition of copper transport induces apoptosis in triple-negative breast cancer cells and suppresses tumor angiogenesis. Mol Cancer Ther. 2019;18:873-85.
49. Inkol JM, Poon AC, Mutsaers AJ. Inhibition of copper chaperones sensitizes human and canine osteosarcoma cells to carboplatin chemotherapy. Vet Comp Oncol. 2020;18:559-69.
50. Li YQ, Yin JY, Liu ZQ, Li XP. Copper efflux transporters ATP7A and ATP7B: novel biomarkers for platinum drug resistance and targets for therapy. IUBMB Life. 2018;70:183-91.
51. Xue Q, Yan D, Chen X, et al. Copper-dependent autophagic degradation of GPX4 drives ferroptosis. Autophagy. 2023;19:1982-96.
52. Chen S, Sun L, Koya K, et al. Syntheses and antitumor activities of N’1,N’3-dialkyl-N’1,N’3-di-(alkylcarbonothioyl) malonohydrazide: the discovery of elesclomol. Bioorg Med Chem Lett. 2013;23:5070-6.
53. Tsvetkov P, Detappe A, Cai K, et al. Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat Chem Biol. 2019;15:681-9.
54. Buccarelli M, D’Alessandris QG, Matarrese P, et al. Elesclomol-induced increase of mitochondrial reactive oxygen species impairs glioblastoma stem-like cell survival and tumor growth. J Exp Clin Cancer Res. 2021;40:228.
55. Zheng P, Zhou C, Lu L, Liu B, Ding Y. Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy. J Exp Clin Cancer Res. 2022;41:271.
56. Zhang D, Li J, Wang F, Hu J, Wang S, Sun Y. 2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy. Cancer Lett. 2014;355:176-83.
57. Kluza J, Corazao-Rozas P, Touil Y, et al. Inactivation of the HIF-1α/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants. Cancer Res. 2012;72:5035-47.
58. Gao J, Wu X, Huang S, Zhao Z, He W, Song M. Novel insights into anticancer mechanisms of elesclomol: More than a prooxidant drug. Redox Biol. 2023;67:102891.
59. Xu L, Sun Y, Li Y, et al. Disulfiram: a Food and Drug Administration-approved multifunctional role in synergistically drug delivery systems for tumor treatment. Int J Pharm. 2022;626:122130.
60. Lu Y, Pan Q, Gao W, et al. Leveraging disulfiram to treat cancer: mechanisms of action, delivery strategies, and treatment regimens. Biomaterials. 2022;281:121335.
61. Ding Y, Huang Z, Luo Y, et al. A fibroblast activation protein α-activatable nanoagent co-delivering diethyldithiocarbamate and copper for tumor therapy and imaging. Acta Biomater. 2024;187:316-27.
62. Ren X, Li Y, Zhou Y, et al. Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis. Redox Biol. 2021;46:102122.
63. Zhang P, Zhou C, Ren X, et al. Inhibiting the compensatory elevation of xCT collaborates with disulfiram/copper-induced GSH consumption for cascade ferroptosis and cuproptosis. Redox Biol. 2024;69:103007.
64. Chen D, Cui QC, Yang H, Dou QP. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res. 2006;66:10425-33.
65. Cater MA, Haupt Y. Clioquinol induces cytoplasmic clearance of the X-linked inhibitor of apoptosis protein (XIAP): therapeutic indication for prostate cancer. Biochem J. 2011;436:481-91.
66. Cater MA, Pearson HB, Wolyniec K, et al. Increasing intracellular bioavailable copper selectively targets prostate cancer cells. ACS Chem Biol. 2013;8:1621-31.
67. Lu X, Chen X, Lin C, et al. Elesclomol loaded copper oxide nanoplatform triggers cuproptosis to enhance antitumor immunotherapy. Adv Sci. 2024;11:e2309984.
68. Zhang J, Han M, Zhang J, et al. Syphilis mimetic nanoparticles for cuproptosis-based synergistic cancer therapy via reprogramming copper metabolism. Int J Pharm. 2023;640:123025.
69. Chang J, Yin W, Zhi H, et al. Copper deposition in polydopamine nanostructure to promote cuproptosis by catalytically inhibiting copper exporters of tumor cells for cancer immunotherapy. Small. 2024;20:e2308565.
70. Zhang N, Ping W, Rao K, et al. Biomimetic copper-doped polypyrrole nanoparticles induce glutamine metabolism inhibition to enhance breast cancer cuproptosis and immunotherapy. J Control Release. 2024;371:204-15.
71. Xu Y, Liu SY, Zeng L, et al. An enzyme-engineered nonporous copper(I) coordination polymer nanoplatform for cuproptosis-based synergistic cancer therapy. Adv Mater. 2022;34:e2204733.
72. Du C, Guo X, Qiu X, et al. Self-reinforced bimetallic mito-jammer for Ca2+ overload-mediated cascade mitochondrial damage for cancer cuproptosis sensitization. Adv Sci. 2024;11:e2306031.
73. Li Y, Liu J, Weichselbaum RR, Lin W. Mitochondria-targeted multifunctional nanoparticles combine cuproptosis and programmed cell death-1 downregulation for cancer immunotherapy. Adv Sci. 2024;11:e2403520.
74. Huang H, Guo H, Liu J, et al. Dendrimer/metal-phenolic nanocomplexes encapsulating CuO2 for targeted magnetic resonance imaging and enhanced ferroptosis/cuproptosis/chemodynamic therapy by regulating the tumor microenvironment. Acta Biomater. 2024;183:252-63.
75. Lu S, Tian H, Li B, et al. An ellagic acid coordinated copper-based nanoplatform for efficiently overcoming cancer chemoresistance by cuproptosis and synergistic inhibition of cancer cell stemness. Small. 2024;20:e2309215.
76. Lu Y, Pan Q, Gao W, Pu Y, He B. Reversal of cisplatin chemotherapy resistance by glutathione-resistant copper-based nanomedicine via cuproptosis. J Mater Chem B. 2022;10:6296-306.
77. Yang F, Jia L, Zhou HC, et al. Deep learning enables the discovery of a novel cuproptosis-inducing molecule for the inhibition of hepatocellular carcinoma. Acta Pharmacol Sin. 2024;45:391-404.
78. Wang W, Lu K, Jiang X, et al. Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer. J Exp Clin Cancer Res. 2023;42:142.
79. Huang Q, Yang J, Zhang J, et al. Eupalinolide B suppresses pancreatic cancer by ROS generation and potential cuproptosis. iScience. 2024;27:110496.
80. Yang X, Deng L, Diao X, et al. Targeting cuproptosis by zinc pyrithione in triple-negative breast cancer. iScience. 2023;26:108218.
81. Nie X, Chen H, Xiong Y, Chen J, Liu T. Anisomycin has a potential toxicity of promoting cuproptosis in human ovarian cancer stem cells by attenuating YY1/lipoic acid pathway activation. J Cancer. 2022;13:3503-14.
82. Yang Y, Liang S, Geng H, et al. Proteomics revealed the crosstalk between copper stress and cuproptosis, and explored the feasibility of curcumin as anticancer copper ionophore. Free Radic Biol Med. 2022;193:638-47.
83. Zhang W, Chen C, Shi H, et al. Curcumin is a biologically active copper chelator with antitumor activity. Phytomedicine. 2016;23:1-8.
84. Liu Z, Ma H, Lai Z. The role of ferroptosis and cuproptosis in curcumin against hepatocellular carcinoma. Molecules. 2023;28:1623.
85. Sun L, Zhang Y, Yang B, et al. Lactylation of METTL16 promotes cuproptosis via m6A-modification on FDX1 mRNA in gastric cancer. Nat Commun. 2023;14:6523.
86. Katano K, Kondo A, Safaei R, et al. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res. 2002;62:6559-65.
87. Komatsu M, Sumizawa T, Mutoh M, et al. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res. 2000;60:1312-6.
88. Samimi G, Varki NM, Wilczynski S, Safaei R, Alberts DS, Howell SB. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin Cancer Res. 2003;9:5853-9.
89. Lin X, Okuda T, Holzer A, Howell SB. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol. 2002;62:1154-9.
90. Owatari S, Akune S, Komatsu M, et al. Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. Cancer Res. 2007;67:4860-8.
91. Ishida S, McCormick F, Smith-McCune K, Hanahan D. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell. 2010;17:574-83.
92. Zhang X, Jiang Q, Su Y, et al. AMPK phosphorylates and stabilises copper transporter 1 to synergise metformin and copper chelator for breast cancer therapy. Br J Cancer. 2023;128:1452-65.
93. Zhang W, Shi H, Chen C, et al. Curcumin enhances cisplatin sensitivity of human NSCLC cell lines through influencing Cu-Sp1-CTR1 regulatory loop. Phytomedicine. 2018;48:51-61.
94. Shi X, Li Y, Jia M, et al. A novel copper chelator for the suppression of colorectal cancer. Drug Dev Res. 2023;84:312-25.
95. Wangpaichitr M, Wu C, You M, et al. N’,N’-Dimethyl-N’,N’-bis(phenylcarbonothioyl) propanedihydrazide (Elesclomol) selectively kills cisplatin resistant lung cancer cells through reactive oxygen species (ROS). Cancers. 2009;1:23-38.
96. Cierlitza M, Chauvistré H, Bogeski I, et al. Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations. Exp Dermatol. 2015;24:155-7.
97. Sun Y, Xu H, Chen X, Li X, Luo B. Inhibition of mitochondrial respiration overcomes hepatocellular carcinoma chemoresistance. Biochem Biophys Res Commun. 2019;508:626-32.
98. Denise C, Paoli P, Calvani M, et al. 5-fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits. Oncotarget. 2015;6:41706-21.
99. Corazao-Rozas P, Guerreschi P, Jendoubi M, et al. Mitochondrial oxidative stress is the Achille’s heel of melanoma cells resistant to Braf-mutant inhibitor. Oncotarget. 2013;4:1986-98.
100. Monk BJ, Kauderer JT, Moxley KM, et al. A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: an NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2018;151:422-7.
101. O’Day SJ, Eggermont AM, Chiarion-Sileni V, et al. Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. J Clin Oncol. 2013;31:1211-8.
102. Berkenblit A, Eder JP Jr, Ryan DP, et al. Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Clin Cancer Res. 2007;13:584-90.
103. Liu P, Kumar IS, Brown S, et al. Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells. Br J Cancer. 2013;109:1876-85.
104. Yang Z, Guo F, Albers AE, Sehouli J, Kaufmann AM. Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines. Biomed Pharmacother. 2019;113:108727.
105. Guo X, Xu B, Pandey S, et al. Disulfiram/copper complex inhibiting NFkappaB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines. Cancer Lett. 2010;290:104-13.
106. Wang W, McLeod HL, Cassidy J. Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer. 2003;104:504-11.
107. Wang Y, Chen Y, Zhang J, et al. Cuproptosis: a novel therapeutic target for overcoming cancer drug resistance. Drug Resist Updat. 2024;72:101018.
108. Wen H, Qu C, Wang Z, et al. Cuproptosis enhances docetaxel chemosensitivity by inhibiting autophagy via the DLAT/mTOR pathway in prostate cancer. FASEB J. 2023;37:e23145.
109. Gao X, Zhao H, Liu J, et al. Enzalutamide sensitizes castration-resistant prostate cancer to copper-mediated cell death. Adv Sci. 2024;11:e2401396.
110. Li P, Sun Q, Bai S, Wang H, Zhao L. Combination of the cuproptosis inducer disulfiram and anti‑PD‑L1 abolishes NSCLC resistance by ATP7B to regulate the HIF‑1 signaling pathway. Int J Mol Med. 2024;53:19.
111. Jin Y, Wu Q, Pan S, et al. Baicalein enhances cisplatin sensitivity in cervical cancer cells by promoting cuproptosis through the Akt pathway. Biomed Pharmacother. 2024;179:117415.
112. Gao Y, Jin F, Zhang P, et al. Elesclomol-copper synergizes with imidazole ketone erastin by promoting cuproptosis and ferroptosis in myelodysplastic syndromes. Biomed Pharmacother. 2024;175:116727.
113. Liu Z, Sun M, Lu K, et al. The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1) expression. PLoS One. 2013;8:e77293.
114. Raju GSR, Pavitra E, Bandaru SS, et al. HOTAIR: a potential metastatic, drug-resistant and prognostic regulator of breast cancer. Mol Cancer. 2023;22:65.
115. Wang J, Xie S, Yang J, et al. The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy. J Hematol Oncol. 2019;12:81.
116. Wei M, Lu L, Luo Z, Ma J, Wang J. Prognostic analysis of hepatocellular carcinoma based on cuproptosis -associated lncRNAs. BMC Gastroenterol. 2024;24:142.
117. Wang X, Shi Y, Shi H, et al. MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis. J Exp Clin Cancer Res. 2024;43:68.
118. Quan B, Liu W, Yao F, et al. LINC02362/hsa-miR-18a-5p/FDX1 axis suppresses proliferation and drives cuproptosis and oxaliplatin sensitivity of hepatocellular carcinoma. Am J Cancer Res. 2023;13:5590-609.
119. Chen T, Liu Z, Zeng W, Huang T. Down-regulation of long non-coding RNA HOTAIR sensitizes breast cancer to trastuzumab. Sci Rep. 2019;9:19881.
120. Li Z, Qian J, Li J, Zhu C. Knockdown of lncRNA-HOTAIR downregulates the drug-resistance of breast cancer cells to doxorubicin via the PI3K/AKT/mTOR signaling pathway. Exp Ther Med. 2019;18:435-42.
121. Dong C, Feng W, Xu W, et al. The coppery age: copper (Cu)-involved nanotheranostics. Adv Sci. 2020;7:2001549.
